IDT Australia Limited– Earnings Recovery Driven by Strategic Realignment and Cost Optimisation
IDT Australia Limited (ASX: IDT) reported a marked improvement in H1 FY26 performance, reflecting early benefits from its strategic reset and operational restructuring. Revenue from its three core verticals increased 20.3% to AU$8.4 million, led by strong momentum in API Manufacturing and Specialty Orals.
EBITDA improved significantly to a loss of AU$0.4 million compared to a AU$2.7 million loss in the prior corresponding period, demonstrating enhanced operating leverage and tighter cost control. Operating expenses declined 14.2%, delivering AU$1.1 million in savings, while forecast annualised cost reductions have been lifted to AU$2 million through digitisation and automation initiatives. API revenue surged 191.4% to AU$3.0 million, underscoring management’s renewed focus on high-value, scalable contracts. Despite softer Sterile Fill revenue due to project timing, the company enters the second half with a strengthened pipeline and a clearer pathway toward near-term operating profitability and sustainable growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
IDT Australia Limited– Earnings Recovery Driven by Strategic Realignment and Cost Optimisation
IDT Australia Limited (ASX: IDT) reported a marked improvement in H1 FY26 performance, reflecting early benefits from its strategic reset and operational restructuring. Revenue from its three core verticals increased 20.3% to AU$8.4 million, led by strong momentum in API Manufacturing and Specialty Orals.
EBITDA improved significantly to a loss of AU$0.4 million compared to a AU$2.7 million loss in the prior corresponding period, demonstrating enhanced operating leverage and tighter cost control. Operating expenses declined 14.2%, delivering AU$1.1 million in savings, while forecast annualised cost reductions have been lifted to AU$2 million through digitisation and automation initiatives. API revenue surged 191.4% to AU$3.0 million, underscoring management’s renewed focus on high-value, scalable contracts. Despite softer Sterile Fill revenue due to project timing, the company enters the second half with a strengthened pipeline and a clearer pathway toward near-term operating profitability and sustainable growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au